Literature DB >> 2147668

Selective advantage of fra (X) heterozygotes.

F Vogel1, W E Crusio, C Kovac, J P Fryns, M Freund.   

Abstract

The high incidence of the fra (X) syndrome (about 1:2000 male newborns) requires an explanation in view of the low fitness of mentally retarded hemizygous males and heterozygous females. In the past, it has been proposed that the mutation rate may be unusually high, and that mutations occur exclusively in male germ cells. According to an alternative hypothesis, a moderately high mutation rate might combine with a selective advantage of clinically unaffected heterozygotes. In earlier studies, such a combined hypothesis was shown to lead to plausible implications regarding mutation rate and fitness. Moreover, a mutation rate in male germ cells of the magnitude required by the exclusive mutation hypothesis was excluded by studies on comprehensive pedigree data. In this third study in the series, an increased fitness of heterozygous females is demonstrated directly by a comparison of the reproductive performance of heterozygotes with that of adequate controls (mothers and grandparents of Down's syndrome patients). Since, average numbers of children have decreased during recent decades in populations of industrialized countries, heterozygotes (mothers of affected probands and their female relatives in their own generation) were subdivided into those born before and after 1940. Moreover, sibship sizes of probands' mothers and fathers were analyzed separately for family branches in which the fra (X) trait segregated (mostly the maternal branch), or did not segregate (in most instances the paternal branch). In all four categories reproductive performance in heterozygotes was found to be higher than in the controls. This difference was significant statistically for two of the four groups; it was small and nonsignificant only for the parental family branch in which the fra (X) mutant did not segregate and for mothers born after 1940. Fitness estimates ranged between 1.11 and 1.36. A higher incidence of dizygotic twinning suggests a biological component for this increased fertility. On the other hand, fra (X) families have a significantly lower social status than the controls. This suggests a socio-psychological component of their higher fertility. Apparently, both components contribute to their fertility; at present, their relative importance cannot be assessed.

Entities:  

Mesh:

Year:  1990        PMID: 2147668     DOI: 10.1007/bf00205167

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  18 in total

1.  Parental inheritance and psychological disability in fragile X females.

Authors:  A L Reiss; L Freund; S Vinogradov; R Hagerman; A Cronister
Journal:  Am J Hum Genet       Date:  1989-11       Impact factor: 11.025

2.  [The incidence of twin births].

Authors:  P Propping; J Krüger
Journal:  Dtsch Med Wochenschr       Date:  1976-03-26       Impact factor: 0.628

3.  A probable sex difference in some mutation rates.

Authors:  F Vogel
Journal:  Am J Hum Genet       Date:  1977-05       Impact factor: 11.025

4.  Recurrent mutation pressure does not explain the prevalence of the marker (X) syndrome.

Authors:  F Vogel; J Krüger; K B Nielsen; J P Fryns; D Schindler; A Schinzel; A Schmidt; E Schwinger
Journal:  Hum Genet       Date:  1985       Impact factor: 4.132

5.  The marker (X) syndrome: a cytogenetic and genetic analysis.

Authors:  S L Sherman; N E Morton; P A Jacobs; G Turner
Journal:  Ann Hum Genet       Date:  1984-01       Impact factor: 1.670

Review 6.  Spontaneous mutation in man.

Authors:  F Vogel; R Rathenberg
Journal:  Adv Hum Genet       Date:  1975

7.  Heterozygous female carriers of the marker-X-chromosome: IQ estimation and replication status of fra(X)(q).

Authors:  J Paul; U Froster-Iskenius; W Moje; E Schwinger
Journal:  Hum Genet       Date:  1984       Impact factor: 4.132

8.  Heritable fragile sites on human chromosomes. VIII. Preliminary population cytogenetic data on the folic-acid-sensitive fragile sites.

Authors:  G R Sutherland
Journal:  Am J Hum Genet       Date:  1982-05       Impact factor: 11.025

9.  Further segregation analysis of the fragile X syndrome with special reference to transmitting males.

Authors:  S L Sherman; P A Jacobs; N E Morton; U Froster-Iskenius; P N Howard-Peebles; K B Nielsen; M W Partington; G R Sutherland; G Turner; M Watson
Journal:  Hum Genet       Date:  1985       Impact factor: 4.132

10.  Nonspecific X-linked mental retardation II: the frequency in British Columbia.

Authors:  D S Herbst; J R Miller
Journal:  Am J Med Genet       Date:  1980
View more
  7 in total

1.  Estimating the stability of the proposed imprinted state of the fragile-X mutation when transmitted by females.

Authors:  P J Follette; C D Laird
Journal:  Hum Genet       Date:  1992-01       Impact factor: 4.132

2.  Selective advantage of fra (X) heterozygotes compared with mothers of Down syndrome probands?

Authors:  P H Jongbloet
Journal:  Hum Genet       Date:  1992-03       Impact factor: 4.132

3.  At what rate do new premutation alleles arise at the fragile X locus?

Authors:  Diane P Genereux; Charles D Laird
Journal:  Hum Genet       Date:  2013-04-07       Impact factor: 4.132

Review 4.  Risk calculations for hereditary effects of ionizing radiation in humans.

Authors:  F Vogel
Journal:  Hum Genet       Date:  1992-05       Impact factor: 4.132

5.  Between-generation differences in ascertainment and penetrance: relevance to genetic hypotheses in fragile X.

Authors:  D Z Loesch; L J Sheffield; D A Hay
Journal:  Hum Genet       Date:  1993-06       Impact factor: 4.132

6.  Origins of the fragile X syndrome mutation.

Authors:  M C Hirst; S J Knight; Z Christodoulou; P K Grewal; J P Fryns; K E Davies
Journal:  J Med Genet       Date:  1993-08       Impact factor: 6.318

7.  Evolutionary explanations in medical and health profession courses: are you answering your students' "why" questions?

Authors:  Eugene E Harris; Avelin A Malyango
Journal:  BMC Med Educ       Date:  2005-05-10       Impact factor: 2.463

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.